|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 365 GBX | -0.54% |
|
-2.67% | +3.55% |
| 05-22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
| 05-22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
MaxCyte, Inc. affirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance. MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023.
SPL Program-related revenue is now expected to be approximately $5 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR?s CASGEVY?.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.55% | 486M | |
| +10.03% | 223B | |
| +13.59% | 195B | |
| +20.01% | 144B | |
| +30.83% | 111B | |
| +2.05% | 65.01B | |
| +15.38% | 53.02B | |
| +3.96% | 50.45B | |
| +8.37% | 44.15B | |
| +3.27% | 36.45B |
MAXCYTE, INC. 
